FOXM1 and glioma: So we concluded that MYBL2 is of importance downstream factor of Akt/FoxM1 signaling to stimulate advancement of glioma, and could be considered as a promising gene for molecular targeting therapy and biomarker for radiotherapy of glioma (Zhang et al., 2017).